Aquestive adds 20% as epinephrine sublingual film outperforms autoinjector

Sep. 27, 2022 8:01 AM ETAquestive Therapeutics, Inc. (AQST)VTRSBy: Dulan Lokuwithana, SA News Editor2 Comments

Anaphylaxis text on sticky notes with office desk. Healthcare/Medical concept

syahrir maulana/iStock via Getty Images

Aquestive Therapeutics, Inc. (NASDAQ:AQST) gained ~20% pre-market Tuesday after the company announced that its AQST-109 epinephrine sublingual film compared favorably to other forms of epinephrine treatments, including EpiPen® autoinjector of Viatris (VTRS).

Faster delivery of epinephrine

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.